Q2 2026 saw double-digit revenue and profit growth, driven by strong performance in affordable medicines, specialty, and biosimilars. The pending Kashiv acquisition will create a fully integrated biosimilar platform, while guidance for 2026 was raised across all key metrics.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.